Premium
T‐cell lymphoma: morphology, immunophenotype and clinical features
Author(s) -
KRAJEWSKI A. S.,
MYSKOW M. W.,
CACHIA P. G.,
SALTER D. M.,
SHEEHAN T.,
DEWAR A. E.
Publication year - 1988
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1988.tb02001.x
Subject(s) - mycosis fungoides , immunophenotyping , lymphoma , medicine , peripheral t cell lymphoma , stage (stratigraphy) , large cell , pathology , lymph node , t cell lymphoma , lymphoblastic lymphoma , chemotherapy , t cell , cancer , immunology , antigen , biology , immune system , adenocarcinoma , paleontology
The histology, immunophenotype and clinical presentation of 43 cases of T‐cell lymphoma are described. Cases were classified into nine types; T‐lymphocytic lymphoma (three), mycosis fungoides (six), Sézary syndrome (two), T‐zone lymphoma (13), angio‐immunoblastic lymphadenopathy (AIL)‐like T‐cell lymphoma (five), pleomorphic medium cell (one), large cell immunoblastic (four), large cell polylobated (five) and lymphoblastic (four). The patients comprised 26 males and 17 females aged between 15 and 86 years. The majority showed disseminated disease at the time of diagnosis (18 stage IV, nine stage III, five stage II, eight stage I and three cases not staged). Thirty‐one patients showed lymph node involvement. Cutaneous involvement was a common finding (18 cases, 10 cases excluding mycosis fungoides and Sézary syndrome). Details of therapy and clinical follow‐up were obtained in 37 cases. With simple chemotherapy only one complete response (7%, 1/16) was obtained. With aggressive therapy 48% (13/27) of patients showed complete responses. Twenty patients died during the follow‐up period. Life table analysis showed a 58% probability of surviving 1 year and 36% probability of surviving 3 years. There was a significant difference in survival probability between low/intermediate‐grade (lymphocytic, Sézary syndrome, mycosis fungoides and T‐zone lymphoma including AIL‐type) lymphomas and high‐grade (large cell immunoblastic and polylobated and lymphoblastic) lymphomas ( P <0.025). However, when survival of T‐zone and AIL‐like T‐cell lymphoma was compared with survival of large cell immunoblastic and polylobated lymphomas no significant difference was detected. Age (< 50 years) and stage I or II disease were associated with significantly better survival ( P <0.005 and P <0.05).